BIOMARKER IN INFLAMMATORY DISEASES

• US 20080145883A1
• Filed: 10/03/2007
• Published: 06/19/2008
• Est. Priority Date: 10/09/2006
• Status: Abandoned Application

• Current Assignee: Alexander Wlachos, Andreas Billich, Diana Mechtcheriakova, Thomas Baumruker
• Original Assignee: Alexander Wlachos, Andreas Billich, Diana Mechtcheriakova, Thomas Baumruker
• Inventors: Billich, Andreas, Wlachos, Alexander, Mechtcheriakova, Diana, Baumruker, Thomas
• Application Number:
  US11/866,621
• Publication Number:
  US 20080145883A1
• Time in Patent Office: Days
• US Class Current: 435/21
• CPC Class Codes: C12Q 1/42 involving phosphatase
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2800/205 Scaling palpular diseases, e.g. psoriasis, pytiriasis
• CPC Class Codes: G01N 2800/24 Immunology or allergic disorders SLE G01N2800/104
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The use of SPP2 as a target in inflammatory responses, e.g. as a biomarker, e.g. for immune disorders associated with inflammation, such as psoriasis; diagnostic kits comprising means for determining the level of SPP2 and a method for identifying agents that modulates SPP2 activity.

Claims

1. A kit for diagnosing a disorder which is mediated by high levels of SPP2 or by SPP2 activity in a sample of an individual comprising:

a) means for detecting the level of SPP2 in a sample;

b) instructions how to use said kit in dendritic cells;

c) a detection means; and

d) a solid phase.

2. A kit according to claim 1, wherein the disorder is mediated by high levels of SPP2.

3. A kit according to claim 1, wherein the disorder is an inflammatory immune disorder.

4. A kit according to claim 1, wherein the disorder is psoriasis.

5. A method for diagnosing a disorder which is mediated by high levels of SPP2 or by SPP2 activity, comprising the steps of:

a) providing a sample of an individual;

b) determining the level of SPP2 in said sample;

c) comparing the level of SPP2 as determined in step b) with a reference level; and

d) diagnosing a disorder or disease, if the SPP2 level in the sample is elevated compared with the reference level.

6. A method according to claim 5, wherein the disorder is mediated by high levels of SPP2.

7. A method of monitoring the therapeutic efficacy in the treatment of an individual with a substance which is expected to have an effect on reducing or curing a disorder which is mediated by elevated SPP2 levels or SPP2 activity, which method comprises the steps of determining the level of SPP2 in dendritic cells in a sample of said individual suffering from such disease and comparing the level determined with the level of SPP2 prior to administration of said substance.

8. A method according to claim 7, wherein the disorder is mediated by high levels of SPP2.

9. An assay for identifying an agent that mediates a disorder which is mediated by elevated SPP2 levels or SPP2 activity, comprising the steps of:

a) determining the level of SPP2 in cells of a sample of an individual, in the absence and in the presence of a candidate compound which may be expected to modulate the level of SPP2;

b) identifying a candidate compound which modulates the level of SPP2 as determined in step a) as an agent; and

c) using such agent as a pharmaceutical in the treatment of disorders mediated by elevated SPP2 levels or SPP2 activity.

10. An assay according to claim 9, wherein the disorder is mediated by high levels of SPP2.